卫光生物
(002880)
| 流通市值：63.28亿 | | | 总市值：63.28亿 |
| 流通股本：2.27亿 | | | 总股本：2.27亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 192,334,599.44 | 356,018,048.66 | 311,172,989.53 | 294,587,016.71 |
| 应收票据及应收账款 | 162,923,485.58 | 89,742,485.34 | 183,054,334.28 | 208,459,299.44 |
| 其中：应收票据 | 98,146,807.92 | 43,849,508.81 | 97,557,109.09 | 105,614,919.75 |
| 应收账款 | 64,776,677.66 | 45,892,976.53 | 85,497,225.19 | 102,844,379.69 |
| 预付款项 | 16,518,430.18 | 7,490,466.04 | 14,209,668.86 | 12,296,276.64 |
| 其他应收款合计 | 3,544,453.99 | 3,480,610 | 3,103,705.89 | 4,650,857.85 |
| 存货 | 687,633,973.81 | 677,390,893.08 | 652,650,787.79 | 605,510,451.16 |
| 其他流动资产 | 15,704,879.13 | 10,074,199.68 | 1,025,530.39 | 7,619,677.42 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,078,659,822.13 | 1,144,196,702.8 | 1,165,217,016.74 | 1,133,123,579.22 |
| 非流动资产: | | | | |
| 其他非流动金融资产 | 84,492,952.29 | 83,492,952.29 | 83,492,952.29 | 83,492,952.29 |
| 投资性房地产 | 93,436,961.71 | 25,842,213.35 | 18,958,840.58 | 19,151,615.04 |
| 固定资产 | 972,074,317.53 | 498,359,498.41 | 485,909,663 | 491,490,687.17 |
| 在建工程 | 131,470,343.27 | 599,839,093.76 | 600,284,302.24 | 536,423,559.18 |
| 使用权资产 | 16,170,734.13 | 16,385,432.16 | 16,600,130.19 | 16,961,311.86 |
| 无形资产 | 75,095,785.25 | 75,582,704.84 | 76,428,758.51 | 75,108,706.26 |
| 开发支出 | 19,644,976.41 | 19,644,976.41 | 19,644,976.41 | 19,644,976.41 |
| 商誉 | 19,230,057.19 | 19,230,057.19 | 19,230,057.19 | 19,230,057.19 |
| 长期待摊费用 | 2,182,342.39 | 2,613,567.61 | 3,044,792.83 | 3,129,351.39 |
| 递延所得税资产 | 4,280,739.73 | 2,338,437.72 | 2,411,977.89 | 2,507,625.52 |
| 其他非流动资产 | 168,729,245.89 | 169,071,025.88 | 165,052,911.03 | 175,469,400.73 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,586,808,455.79 | 1,512,399,959.62 | 1,491,059,362.16 | 1,442,610,243.04 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 2,665,468,277.92 | 2,656,596,662.42 | 2,656,276,378.9 | 2,575,733,822.26 |
| 流动负债: | | | | |
| 短期借款 | - | - | 100,000,000 | 100,086,111.11 |
| 应付票据及应付账款 | 21,164,463.58 | 30,000,095.38 | 35,616,633.08 | 33,144,547.16 |
| 应付账款 | 21,164,463.58 | 30,000,095.38 | 35,616,633.08 | 33,144,547.16 |
| 预收款项 | - | - | - | 12,341 |
| 合同负债 | 4,923,344.32 | 4,511,998.87 | 3,252,091.27 | 7,797,263.27 |
| 应付职工薪酬 | 41,088,055.73 | 40,345,056.04 | 33,410,659.95 | 52,809,061.31 |
| 应交税费 | 11,790,556.31 | 13,154,666.88 | 11,185,884.72 | 13,428,798.03 |
| 其他应付款合计 | 88,673,757.32 | 36,303,199.57 | 27,196,709.75 | 20,969,666.68 |
| 应付股利 | 45,360,000 | - | - | - |
| 一年内到期的非流动负债 | 207,900 | 519,750 | 831,600 | 1,316,250 |
| 其他流动负债 | 113,738.07 | 101,397.71 | 63,600.48 | 191,465.07 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 167,961,815.33 | 124,936,164.45 | 211,557,179.25 | 229,755,503.63 |
| 非流动负债: | | | | |
| 长期借款 | 451,869,558.89 | 490,145,299.91 | 481,576,180.58 | 428,961,954.68 |
| 租赁负债 | 17,319,928.29 | 17,135,554.74 | 16,948,191.66 | 16,659,210.81 |
| 递延收益 | 47,886,543.87 | 49,049,625.06 | 26,126,927.86 | 25,915,130.2 |
| 递延所得税负债 | 856,352.67 | 856,352.67 | 856,352.67 | 856,352.67 |
| 其他非流动负债 | 6,052,122.45 | 6,053,927.58 | 6,051,963.19 | 6,051,545.3 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 523,984,506.17 | 563,240,759.96 | 531,559,615.96 | 478,444,193.66 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 691,946,321.5 | 688,176,924.41 | 743,116,795.21 | 708,199,697.29 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 226,800,000 | 226,800,000 | 226,800,000 | 226,800,000 |
| 资本公积 | 574,502,470.18 | 574,502,470.18 | 574,502,470.18 | 574,502,470.18 |
| 盈余公积 | 148,058,610.31 | 148,058,610.31 | 148,058,610.31 | 148,058,610.31 |
| 未分配利润 | 997,347,558.75 | 992,473,536.85 | 937,184,029.96 | 891,447,985.63 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,946,708,639.24 | 1,941,834,617.34 | 1,886,545,110.45 | 1,840,809,066.12 |
| 少数股东权益 | 26,813,317.18 | 26,585,120.67 | 26,614,473.24 | 26,725,058.85 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,973,521,956.42 | 1,968,419,738.01 | 1,913,159,583.69 | 1,867,534,124.97 |
| 负债和股东权益合计 | 2,665,468,277.92 | 2,656,596,662.42 | 2,656,276,378.9 | 2,575,733,822.26 |
| 公告日期 | 2023-10-26 | 2023-08-25 | 2023-04-26 | 2023-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |